ACTIV-2：一项评估新型治疗药物治疗门诊早期 COVID-19 的平台试验。
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
机构信息
Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA.
Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
出版信息
J Infect Dis. 2023 Aug 31;228(Suppl 2):S77-S82. doi: 10.1093/infdis/jiad246.
Abstract
Clinical Trials Registration ClinicalTrials.gov Identifier: NCT04518410.
摘要
临床试验注册 临床试验.gov 标识符：NCT04518410。
相似文献
1
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.ACTIV-2：一项评估新型治疗药物治疗门诊早期 COVID-19 的平台试验。
J Infect Dis. 2023 Aug 31;228(Suppl 2):S77-S82. doi: 10.1093/infdis/jiad246.
2
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.孟鲁司特治疗 COVID-19 门诊患者的持续康复时间：ACTIV-6 随机临床试验。
JAMA Netw Open. 2024 Oct 1;7(10):e2439332. doi: 10.1001/jamanetworkopen.2024.39332.
3
Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings.加拿大社区环境中 COVID 治疗适应性平台试验（CanTreatCOVID）：社区环境中急性 SARS-CoV-2 感染治疗随机对照适应性平台试验方案
BMJ Open. 2025 Aug 3;15(8):e097134. doi: 10.1136/bmjopen-2024-097134.
4
Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study.SARS-CoV-2奥密克戎变异株时代早期抗SARS治疗对严重免疫功能低下的COVID-19门诊患者的真实世界疗效：一项倾向评分调整的回顾性队列研究
J Antimicrob Chemother. 2024 Dec 2;79(12):3248-3253. doi: 10.1093/jac/dkae351.
5
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.在随机平台试验中，将不同安慰剂作为对照组：来自 ACTIV-2 COVID-19 试验的经验的获益和挑战。
J Infect Dis. 2023 Aug 31;228(Suppl 2):S92-S100. doi: 10.1093/infdis/jiad209.
6
Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials.COVID-19 住院成人的被动免疫疗法：六项随机对照试验的个体参与者数据荟萃分析
PLoS Med. 2025 Jul 7;22(7):e1004616. doi: 10.1371/journal.pmed.1004616. eCollection 2025 Jul.
7
Examining the bias-efficiency tradeoff from incorporation of nonconcurrent controls in platform trials: A simulation study example from the adaptive COVID-19 treatment trial.考察平台试验中纳入非同期对照所带来的偏倚-效率权衡：来自适应性COVID-19治疗试验的模拟研究示例
Clin Trials. 2025 Feb 8:17407745251313928. doi: 10.1177/17407745251313928.
8
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.针对 COVID-19 的抗体和细胞疗法：一项实时系统评价和网络荟萃分析。
BMJ. 2021 Sep 23;374:n2231. doi: 10.1136/bmj.n2231.
9
Janus kinase inhibitors for the treatment of COVID-19.Janus 激酶抑制剂治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209.
10
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation.奈玛特韦/利托那韦和莫努匹拉韦对门诊新冠康复者预后的疗效：一项目标试验模拟研究
Emerg Microbes Infect. 2025 Dec;14(1):2469648. doi: 10.1080/22221751.2025.2469648. Epub 2025 Mar 4.
引用本文的文献
1
Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings.加拿大社区环境中 COVID 治疗适应性平台试验（CanTreatCOVID）：社区环境中急性 SARS-CoV-2 感染治疗随机对照适应性平台试验方案
BMJ Open. 2025 Aug 3;15(8):e097134. doi: 10.1136/bmjopen-2024-097134.
2
The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death.旨在降低28天住院率和/或死亡率的COVID-19治疗早期试验中病毒载量终点的选择
J Infect Dis. 2025 Jul 30;232(1):60-68. doi: 10.1093/infdis/jiaf282.
3
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial.在突发传染病大流行背景下实施无缝衔接的2/3期研究设计：从ACTIV-2平台新冠治疗试验中汲取的经验教训
Contemp Clin Trials. 2025 Jun;153:107887. doi: 10.1016/j.cct.2025.107887. Epub 2025 Mar 25.
4
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.ACTIV-2 试验中替沙格韦单抗/西加韦单抗或安慰剂用于治疗 COVID-19：安全性、药代动力学以及中和抗体和抗药物抗体
iScience. 2025 Feb 4;28(3):111938. doi: 10.1016/j.isci.2025.111938. eCollection 2025 Mar 21.
5
ACTIV trials: cross-trial lessons learned for master protocol implementation.ACTIV试验：主方案实施过程中的跨试验经验教训
J Clin Transl Sci. 2024 Oct 15;8(1):e152. doi: 10.1017/cts.2024.507. eCollection 2024.
6
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.急性 COVID-19 后结局，包括参与者报告的长期 COVID：ACTIV-2 试验中安巴韦单抗/罗米司韦单抗与安慰剂的对比
EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. eCollection 2024 Sep.
7
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.SAB-185 治疗非住院 COVID-19 成人患者的安全性和疗效：一项随机临床试验。
J Infect Dis. 2024 Nov 15;230(5):1177-1186. doi: 10.1093/infdis/jiae369.
8
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19.SARS-CoV-2 血浆抗体和核衣壳抗原状态预测 COVID-19 门诊患者的结局。
Clin Infect Dis. 2024 Oct 15;79(4):920-927. doi: 10.1093/cid/ciae324.
9
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.在一项2期试验中，对非住院COVID-19患者皮下注射SARS-CoV-2中和单克隆抗体组合BMS-986414（C135-LS）和BMS-986413（C144-LS）的安全性、有效性和药代动力学
Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. eCollection 2024.
本文引用的文献
1
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.在非住院的 COVID-19 患者中，组合 SARS-CoV-2 中和单克隆抗体 Amubarvimab 加 Romlusevimab 的安全性和疗效。
Ann Intern Med. 2023 May;176(5):658-666. doi: 10.7326/M22-3428. Epub 2023 Apr 18.
2
Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19.新冠病毒肺炎患者在症状消失2天后症状复发。
JAMA Netw Open. 2022 Oct 3;5(10):e2238867. doi: 10.1001/jamanetworkopen.2022.38867.
3
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.在一项 II 期随机临床试验中，巴利昔单抗治疗期间出现了 SARS-CoV-2 逃逸突变。
Nat Microbiol. 2022 Nov;7(11):1906-1917. doi: 10.1038/s41564-022-01254-1. Epub 2022 Oct 26.
4
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.鼻和血浆严重急性呼吸综合征冠状病毒 2 核酸水平与 COVID-19 非住院成年患者 ACTIV-2 试验中症状缓解时间有关。
Clin Infect Dis. 2023 Feb 18;76(4):734-737. doi: 10.1093/cid/ciac818.
5
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.单克隆抗体治疗可快速促使 SARS-CoV-2 感染转为阴性。
Cell Rep Med. 2022 Jul 19;3(7):100678. doi: 10.1016/j.xcrm.2022.100678. Epub 2022 Jun 20.
6
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.COVID-19 治疗干预和疫苗加速行动（ACTIV）：评估候选 COVID-19 疗法的主方案设计。
Ann Intern Med. 2021 Sep;174(9):1293-1300. doi: 10.7326/M21-1269. Epub 2021 Jun 29.
7
Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics.加速临床前路径，以支持 COVID-19 治疗药物的快速开发。
Cell Host Microbe. 2020 Nov 11;28(5):638-645. doi: 10.1016/j.chom.2020.09.017. Epub 2020 Oct 1.
8
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times.加速COVID-19治疗干预和疫苗（ACTIV）：应对前所未有的时代的前所未有的合作。
JAMA. 2020 Jun 23;323(24):2455-2457. doi: 10.1001/jama.2020.8920.
Zotero 插件